Related Experiment Video

Updated: Apr 6, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.2K

Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast Cancer

Kamila A Marzec1, Robert C Baxter1, Janet L Martin1

  • 1Hormones and Cancer Division, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, St Leonards, NSW 2065, Australia.

Biomed Research International
|July 30, 2015
PubMed

Insights

Triple-negative breast cancer (TNBC) shows high IGFBP-3 and EGFR expression. Cotargeting EGFR and sphingosine kinase-1 (SphK1) shows promise as a novel therapy for TNBC, potentially overcoming treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Insulin-like growth factor binding protein-3 (IGFBP-3) plays a dual role in cancer, acting as both a tumor suppressor and promoter.
  • Triple-negative breast cancer (TNBC) exhibits high IGFBP-3 expression, correlating with poor prognosis and resistance to standard therapies.
  • TNBC lacks targeted treatment options due to the absence of estrogen/progesterone receptors and HER2 overexpression.

Purpose of the Study:

  • To investigate the functional interaction between Epidermal Growth Factor Receptor (EGFR) and IGFBP-3 signaling in TNBC.
  • To explore the potential of cotargeting EGFR and sphingosine kinase-1 (SphK1) as a novel therapeutic strategy for TNBC.
  • To identify mechanisms underlying chemoresistance promoted by EGFR and IGFBP-3 interactions in TNBC.

Main Methods:

  • Preclinical investigation of combined EGFR and SphK1 inhibition in TNBC models.
  • Analysis of functional crosstalk between EGFR and IGFBP-3 signaling pathways.
  • Delineation of molecular mechanisms driving chemoresistance in EGFR- and IGFBP-3-expressing cancers.

Main Results:

  • A functional growth-stimulatory interaction between EGFR and IGFBP-3 signaling was identified in TNBC.
  • Cotargeting EGFR kinase activity and SphK1 demonstrated preclinical promise for TNBC therapy.
  • EGFR and IGFBP-3 interaction may contribute to chemoresistance in TNBC.

Conclusions:

  • Combined inhibition of EGFR and SphK1 represents a promising novel therapeutic approach for TNBC.
  • Understanding the EGFR-IGFBP-3 axis can reveal new therapeutic targets for TNBC and other cancers.
  • Targeting the interplay between EGFR and IGFBP-3 may overcome treatment resistance in specific cancer types.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.8K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K